$11.70 Million in Sales Expected for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) This Quarter

Wall Street brokerages expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to announce $11.70 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Dicerna Pharmaceuticals’ earnings, with the highest sales estimate coming in at $12.93 million and the lowest estimate coming in at $10.00 million. Dicerna Pharmaceuticals reported sales of $1.55 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 654.8%. The firm is scheduled to issue its next earnings report on Monday, November 4th.

On average, analysts expect that Dicerna Pharmaceuticals will report full year sales of $37.25 million for the current financial year, with estimates ranging from $28.80 million to $48.10 million. For the next year, analysts anticipate that the company will post sales of $59.50 million, with estimates ranging from $15.00 million to $100.50 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.03). Dicerna Pharmaceuticals had a negative return on equity of 50.30% and a negative net margin of 737.93%. The company had revenue of $5.68 million for the quarter, compared to the consensus estimate of $10.95 million.



A number of equities analysts have commented on DRNA shares. BidaskClub raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. Citigroup lifted their price objective on shares of Dicerna Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, July 3rd. Chardan Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of Dicerna Pharmaceuticals in a research report on Tuesday, August 13th. HC Wainwright set a $22.00 price objective on shares of Dicerna Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 26th. Finally, B. Riley set a $24.00 price objective on shares of Dicerna Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 3rd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $21.57.

DRNA stock traded up $0.70 during midday trading on Friday, reaching $14.88. 206,700 shares of the company were exchanged, compared to its average volume of 423,013. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.65. The business has a 50-day moving average price of $14.22 and a two-hundred day moving average price of $13.97. Dicerna Pharmaceuticals has a one year low of $9.31 and a one year high of $16.95. The firm has a market capitalization of $968.66 million, a price-to-earnings ratio of -12.40 and a beta of 2.21.

In other news, insider James B. Weissman sold 14,680 shares of Dicerna Pharmaceuticals stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $13.07, for a total transaction of $191,867.60. Following the completion of the sale, the insider now owns 9,800 shares of the company’s stock, valued at $128,086. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 21.28% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of DRNA. UBS Group AG raised its stake in Dicerna Pharmaceuticals by 2.0% in the second quarter. UBS Group AG now owns 2,467,799 shares of the biopharmaceutical company’s stock valued at $38,868,000 after purchasing an additional 48,678 shares in the last quarter. Vanguard Group Inc. raised its stake in Dicerna Pharmaceuticals by 1.6% in the second quarter. Vanguard Group Inc. now owns 2,339,194 shares of the biopharmaceutical company’s stock valued at $36,842,000 after purchasing an additional 35,905 shares in the last quarter. Citadel Advisors LLC raised its stake in Dicerna Pharmaceuticals by 8.1% in the second quarter. Citadel Advisors LLC now owns 2,185,409 shares of the biopharmaceutical company’s stock valued at $34,420,000 after purchasing an additional 163,799 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Dicerna Pharmaceuticals by 54.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 1,152,999 shares of the biopharmaceutical company’s stock valued at $18,160,000 after purchasing an additional 406,960 shares in the last quarter. Finally, Artal Group S.A. raised its stake in Dicerna Pharmaceuticals by 2.1% in the second quarter. Artal Group S.A. now owns 1,000,000 shares of the biopharmaceutical company’s stock valued at $15,750,000 after purchasing an additional 20,725 shares in the last quarter. 82.04% of the stock is owned by institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

See Also: Market Capitalization in the Stock Market

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.